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Abstract  
Globalisation, scientific and technical progress are the basis of numerous innovative therapies for oncologic and 
non-oncologic diseases. It is another matter how much and by whom they are desired, and whether they have to 
be applied. When and how often? Innovative approaches should go towards simplification, universal distribution 
and application while at the same time analysis between the potential initial investment and the achieved final 
result should be made. An illustrative example for this is the targeted therapy for melanoma with its low baseline 
criteria or basic rules for its surgical treatment. Another example could be the confocal microscopy in the context 
of dysplastic nevus syndrome. Therapies for various autoimmune diseases should also be considered critically. In 
the current OAMJMS issue, as well as in some of our other ideas and statements reported also in OAMJMS, we 
are trying to answer at least to a part of these dilemmas, to provoke a critical point of view and to ask some simple 
questions: “Should any innovation be considered as a face value? Which is potentially beneficial for our patients? 
How could we regulate the processes to minimise the need for expensive medications for certain diseases? And, 
of course, we are also turning to our own mistakes by visualising the results of them! 
 
 
 
 
 
 
 
 
 
 
The essential questions in the context of 
progress and evolution in medicine and evolution, in 
general, affect some common human wisdom that is 
often ignored. We desire to be always first, move 
forward, and meanwhile be rich, desirable, glorified 
and famous … these two mutually exclusive directions 
or states of mind, I do not know, ... maybe ... maybe 
they are the reason to repeat our mistakes and not to 
learn from history as a whole? Perhaps the conditions 
for achieving one or another of the goals above are 
mutually exclusive, which gives rise to our subsequent 
absurd and sometimes inconsistent with the common-
sense decisions? We are not able to think humanely, 
universally, reasonably and/or wisely, and meanwhile 
not prejudicing the interests of the status quo or 
someone? And if you harm those – you will be 
imposed “an embargo” by all possible means. The 
least of all is the financial one. Even a public 
reprimand, and ... a universal denial is possible! And 
here we come to the choice ... making the right 
decisions: black or white? Our decisions are followed 
by absurd consequences, or the lack of explicitness or 
the presence of a half-way policy in our decisions is 
followed by absurdities. Grey colour is undesired; it is 
for the politicians. In general, positioning is important. 
It results in a failure or rise. But not in “flickering”. 
Or maybe these statements or rhetorical 
questions are wrong? And we should be chameleons? 
And surely there are such? At least I do not know any 
chameleons in medicine. Do you? Absurdities are a 
common human impediment caused by mercenary 
motives, by difficult to achieve, mutually exclusive 
desires inconsistent with healthy logic, and why not 
partly due to pure egoism? 
Take melanoma and the new 2017 
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classification, for example? Think about the lack of an 
adequate response to questions related to therapeutic 
recommendations in any individual melanoma 
patient? All the way, up to the lack of personalisation 
of medicine in the early stages of the disease. What is 
this, ... you will ask? We will discuss it a bit later! Or 
ignoring important articles from magazines with a high 
impact factor? With very high impact factor! And with 
the highest impact factor! Is this not a serious problem 
– medical, human, health-related, personal? 
Magazines looking for results from multicentre double-
blind, and I would specify – sometimes “totally blind” 
studies, although based on originally mistaken 
baselines? And how could this be admitted? Self-
criticism is inherent to highly intelligent individuals 
only, and these are not always represented in high-
quality, high impact magazines. I would ask, are there 
any editors in those magazines who have not seen 
“living patients”? At the meetings of the magazine 
boards, they usually announce that they will release 2-
3 articles, just like that? A pure desire! Because their 
fingers “itch” to do so! So, how shall we then solve the 
problems related to innovative therapeutic approaches 
and classifications? By turning for advice to whom? 
Why can an editor of such a magazine publish 160 
articles, say in NEJM, or 500 articles in Lancet, and 
cannot give a good answer to the question, “Why are 
you rejecting my article”? Or the answer is, “... 
because we have some other good articles and there 
is no room for you, unfortunately, but ... try 
somewhere else!” Or try again later! In other words, 
the spots are reserved for others? Unfortunately, I did 
not know that bookings were to be made early!? And 
do we have to leave a deposit, hahaha? By bank 
transfer or endowment? Next time I will ask this 
question ... I will do, for sure! When should I post an 
article that is better than 1,000 other articles … which 
is the right moment and are there any vacant spots … 
or maybe articles are less frequently released in 
general? Another interesting question would be, 
“When will logic triumph over lobbyism and 
selfishness? Is Christmas time convenient for you?” 
And when will you consider not only studies 
sponsored by the pharmaceutical industry, but also 
the “cast-iron arguments” of sound logic? These 
sometimes weigh more than sponsorship and fake 
magnanimity! 
Why are certain general human and medical 
or humanity issues being rudely ignored? Why are two 
surgical interventions necessary in certain patients, 
where just one is sufficient [1] [2]? Why the high-
frequency ultrasound approach is not introduced as a 
diagnostic option at least in some melanoma patients 
[1][2][3]? Why don’t we define the fields of surgical 
safety more clearly [1]? Is it necessary to treat 
melanomas of different tumour thickness equally and 
those of the same tumour thickness – differently? 
Who could ensure the freedom to choose a resection 
field, or in other words, its variability? All these 
questions have no definitive answer and are left 
without any possible discussion or optimisation, which 
is, in fact, a simple and not impossible approach. If we 
look a little deeper and a bit earlier into the “shared 
problems”, perhaps we would also conclude that such 
“severe neoplasm” therapy is not so difficult? That the 
clarification of the “starting points” or the so-called 
“baseline criteria” ... might contribute to the lack of 
necessary progress about the millions of funds 
invested in a targeted therapy at a later stage? Funds 
that could be spent somewhere else? The more we 
ask these questions, the more we should think about 
whether these criteria are real, workable, applicable 
and enforceable? And who created them? Why do 
they remain unchanged for such a long time despite 
the misconceptions they contain? And above all, who 
has an interest in this? And for how long? Because, 
maybe ... “TIME IS MONEY”, ... someone said! And 
someone else ... that “medicine is business”! 
Recently, we had patients with melanoma of 
more than 16 and 8 mm who were successfully 
treated just surgically? Without any dissemination 
data. Until eight years ago, chemotherapy or 
polychemotherapy was the standard of care in these 
patient groups? And all of a sudden it was sunk to the 
bottom? Targeting, or OMICS appeared? What would 
we say now if someone suggested dacarbazine, for 
example, in metastatic melanoma? Or prophylactically 
maybe? 
There is light in the tunnel, definitely, but the 
adaptation of tumour cell is amazing. Melanoma 
depends on multiple factors, and OMICS therapy 
(following a genetic typing test) is not available to all 
or at least to the majority of mortal individuals! 
Apparently, apart from “Europe at two speeds”, there 
is also a “different speed” medicine! 
And what shall we say about confocal 
microscopy? Patients with dysplastic nevi? And 
patients with identical clinical, dermatoscopic and 
histopathological signs of two or more lesions? 
Protect them from progression? And/or from 
excisions? It was found that borderline, dysplastic 
and/or normal melanocytic lesions in a patient 
(whether with dysplastic nevi syndrome or not) ... 
could show a different gene pool (based on OMICS 
analysis or another type of testing) and a different 
progression trend within an indefinite period, wasn’t it? 
Well then? Who needed such innovation? I see that 
even the world’s dermatoscopy guru-Prof. Giuseppe 
Argenziano has been a bit sceptical over the years 
about dermatoscopy and confocal microscopy ... but 
my observation is indirect, tacit (personal 
observations)? Or maybe his age has told its heavy 
word and suppressed his emotionality? And then, the 
next step is reconciliation? Who knows? Or is my 
interpretation wrong? Or, rather, his scepticism about 
explicit statements on final diagnosis results from his 
long experience and the lack of definitiveness or 
reduced degree of definitiveness (of methodologies) 
about the final diagnosis!? Then his response to the 
lectures would be, “Then cut it! That’s simple!” And I 
agree with him, but I would like to add that here we 
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come to the following problem, “We have to know 
exactly when to cut it and how to cut it! And that’s not 
very simple. It’s complicated, very ... complicated.” It’s 
a bit easier through the dermatoscope and in front of 
the screen! Problems will start only afterwards. “What 
problems?”, You will ask. 
 
Figure 1: Patient with advanced basal cell carcinoma of the 
forehead, treated inadequately or initially semi-invasive. Gradual 
progression of the disease and involvement of the eyelid. Started 
therapy with Vismodegib presents half-way success 
 
And here, right here, during the categorisation 
of treatment groups of melanoma patients, while 
choosing an approach, we start “limping”, not 
“stumbling”, but literally “limping”, and limping 
seriously! What field should we use to make the “cut”? 
Simply put but well thought out! Shall we use a high-
frequency ultrasound testing, try one-step melanoma 
surgery, explain this individual approach to the 
patient, determine his/her mental condition and 
possible reactions. Or should we proceed with 
excision and possible re-excision, i.e. follow the 
guidelines? Are the clinically determined limitations 
consistent with the histological ones? Why the 
guidelines recommend no re-excision if there is a 
discrepancy of shared limitations? Should I divert from 
the guidelines and ask for an individual consent from 
the patient? How shall I make sure that I am on the 
right track? Scars, lesion localisation, side effects, 
type of anaesthesia? Why no re-excisions are 
recommended at least in patients with nodular and 
superficial melanomas and established differences 
(different clinical and histological limitations following 
the resection) … by the international guidelines? Isn’t 
the histologically proven field of safety more important 
than the clinical one!? This has not been commented 
so far!???? We could define it as an individual 
approach and personalised therapy. Personalization 
that is 100 times more important than personalised, 
targeted therapy in advanced stage patients (Figs 1-
4). As early personalisation may determine the risk of 
progression, and late one 1) is much more expensive, 
and 2) constitutes a constant daily struggle. Late 
personalisation results in progression (Figs. 1-4). It is 
like chasing the wind. Then, each patient should set 
their personalised therapy priorities. Or, if I may 
repeat myself, “We don’t have money, so we have to 
start to think!” 
So, if Prof. Giuseppe Argenziano would 
excuse me for that statement, but I will explicitly state: 
1) “The task of the dermatologic surgeon, the thinking 
dermatologic surgeon, the trying to think and thinking 
at least from time to time ... the dermatologic surgeon 
is much more responsible than the dermatologist's or 
confocalist’s task!” 
It is one thing to watch the screen and say 
what should be done, and another … as they say … is 
simply, “Just do it!” 
 
Figure 2: Patient with locoregional metastatic squamous cell 
carcinoma on the temple region. Massive locoregional metastatic 
process with facial paresis. Treated with cryotherapy with no 
histological verification of a tumour performed before it 
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Some time ago, as a child ... I enjoyed 
watching Kung Fu movies and was excited to the 
highest degree ... I often tried to imitate those 
characters, but in the course of time I found out it was 
not quite simple, as it required serious preparation 
(physical and mental). Moreover, despite the effort, 
implementation of practised movements is not always 
successful in practice. But: Just cut it ..., I still think it’s 
a good expression! A pretty good expression. And I 
stopped watching movies! Or I do it less and less 
frequently! 
 
Figure 3: Patient with massively evolved local metastatic process 
within a histologically proven ameloblastic carcinoma. Surgical 
intervention is planned for removing the giant metastases, parotid 
gland and sublingual gland. Afterwards, postoperative radiotherapy 
will be conducted 
 
Dear colleagues and friends from brotherly 
Macedonia, I hope that this new edition of the 
dermatological book within the high-quality OAMJMS 
of our highly valued and internationally recognized 
friend, scientist and colleague Prof. Mirko Spiroski, will 
give valuable highlights to all of us on how we should 
or should not proceed in certain situations! What are 
the new trends in vitiligo treatment, how to deal with 
rare clinical cases to achieving maximum safety of our 
patients? What should we expect from inadequate 
treatment of skin cancers and are our mistakes 
rectifiable? Is traditional medicine the most reliable 
one? Shall we observe the guidelines, and when this 
is not desired or at least “inhuman”? The thing is that 
before being therapists, we are still and ... I would say, 
though rarely ... or less and less frequently, also 
people! The problems we face as clinicians and 
dermatosurgeons surpass by several levels of 
complexity those of the initial conservative judgment 
and treatment recommendations in melanoma 
patients. More importantly, personalised medicine 
should be launched and is launched exactly at that 
stage and not at the terminal stage. Personalization 
should not be a mere equivalent of cash flows and 
targeted treatment, as well as of shamelessly 
expensive OMICS analyses?! Personalization is free 
of charge! Or at least should be! Personalization is our 
time, enthusiasm, satisfaction to win, our medical 
mind, medical thought, medical approach. 
Personalization is our human duty! 
For estimation is determined by the radical 
nature of the approach and the clear rules – two 
things that are currently missing in the melanoma 
treatment, for example, worldwide. Now and until now. 
Let’s hope this will change in the future, but the desire 
to change the status quo is one thing, and real actions 
– something else. Upgrading of a system that has 
been somewhat built as a “sand tower”, is unthinkable 
for some... colleagues ... and lobbies in medicine – at 
least for now. Then, the forecast should also remain 
relatively the same. As well as our expectations. Plus, 
the applause at congresses and cocktails for how 
great we are! 
 
Figure 4: Giant tumour of the skin with bone tissue involvement in 
an elderly patient with poor social status. Subsequently, an 
amputation of the hand was performed 
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Of course, we should not be absolute 
pessimists. Criticism is necessary to realise at times 
or be aware of what we are forced to do or have done 
so far. And for what reasons. It is not easy to get to 
that point! Some people live all their lives without 
realising what they are doing and why they do it? 
Even to their last breath, it remains a dilemma for 
them. Was it right? I don’t know? 
I began realising what I was doing just after 
17 years of work experience. More or less. And I am 
pleased to have a vision and a quest for something I 
want to change. The system put pressure on me; I 
followed the rules created by others until ... I had a 
little spare time to do some thinking. Even of my 
inadequate actions, which were not to be neglected 
after all? And I discovered my and our omissions ... as 
I had no choice, let alone a lobby! And money too! 
Then I could only be “logically aggressive”. That was 
the only thing I was left! I had no choice!? The 
logically determined verbal aggression (as some say) 
based on “cast iron facts”, expressed as tragic-
comedy scenario (such as this editorial, for example) 
is maybe our only chance to impose innovative, 
different, unconventional opinion, to impose a change, 
generate positive energy to make our colleagues 
leave their comfort zone and bring one or another 
action or undertaking to a successful end. Because 
success is discomfort. And this is certain. Stick to 
early personalisation (Figs 1-4). 
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